Ascendis Pharma A/S
ASND
Peringkat dalam Saham
#1448
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Harga Saham
$239.88
Kapitalisasi Pasar
$14.96B
Perubahan (1 hari)
0.41%
Perubahan (1 tahun)
18.34%
Negara
DK
Perdagangan Ascendis Pharma A/S (ASND)
Kategori
Healthcare
Riwayat harga saham Ascendis Pharma A/S (ASND)
Harga penutupan tertinggi: $228.86 pada 2026-10-01
Harga penutupan terendah: $19.55 pada 2015-01-01
Harga penutupan terendah: $19.55 pada 2015-01-01
Riwayat harga saham Ascendis Pharma A/S dari 2015 hingga 2026
Performa harga saham tahunan
| Tahun | Performa |
|---|---|
| 2026 (TTM) | 11.10% |
| 2025 | 53.71% |
| 2024 | 15.66% |
| 2023 | -2.60% |
| 2022 | -12.93% |
| 2021 | -20.35% |
| 2020 | 42.79% |
| 2019 | 94.20% |
| 2018 | 63.66% |
| 2017 | 87.65% |
| 2016 | 15.96% |
| 2015 | 0.00% |
Harga saham perusahaan atau pesaing serupa
| Perusahaan | Harga saham | Perubahan 1th% | Negara |
|---|---|---|---|
| $525.12 | 23.14% |
US
|
|
| $237.61 | 784.95% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $887.75 | 9.04% |
NL
|
|
| $289.96 | 1.88% |
BE
|
